Comparison between Avience Biomedicals IPO and Sundrex Oil IPO.
Avience Biomedicals IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Sundrex Oil IPO is a SME Bookbuilding proposed to list at NSE SME.
| Avience Biomedicals IPO | Sundrex Oil IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Fintellectual Corporate Advisors Pvt.Ltd. | Affinity Global Capital Market Pvt.Ltd. |
| Registrar | Skyline Financial Services Pvt.Ltd. | Cameo Corporate Services Ltd. |
| Market Maker | Asnani Stock Broker Pvt.Ltd. | Sunflower Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Avience Biomedicals IPO is up to ₹28.53 Cr whereas the issue size of the Sundrex Oil IPO is up to ₹30.62 Cr. The final issue price of Avience Biomedicals IPO is ₹208.00 per share and of Sundrex Oil IPO is ₹86.00 per share.
| Avience Biomedicals IPO | Sundrex Oil IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹196.00 per share | ₹81.00 per share |
| Issue Price (Upper) | ₹208.00 per share | ₹86.00 per share |
| Issue Price (Final) | ₹208.00 per share | ₹86.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 600 shares | 1600 shares |
| Fresh Issue Size | 13,71,600 shares | 35,60,000 shares |
| Fresh Issue Size (Amount) | up to ₹28.53 Cr | up to ₹30.62 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 13,71,600 shares | 35,60,000 shares |
| Issue Size Total (Amount) | up to ₹28.53 Cr | up to ₹30.62 Cr |
Avience Biomedicals IPO opens on Jun 18, 2026, while Sundrex Oil IPO opens on Dec 22, 2025. The closing date of Avience Biomedicals IPO and Sundrex Oil IPO is Jun 22, 2026, and Dec 24, 2025, respectively.
| Avience Biomedicals IPO | Sundrex Oil IPO | |
|---|---|---|
| Anchor Bid Date | Jun 17, 2026 | |
| Issue Open | Jun 18, 2026 | Dec 22, 2025 |
| Issue Close | Jun 22, 2026 | Dec 24, 2025 |
| Basis Of Allotment (Tentative) | Jun 23, 2026 | Dec 26, 2025 |
| Initiation of Refunds (Tentative) | Jun 24, 2026 | Dec 29, 2025 |
| Credit of Share (Tentative) | Jun 24, 2026 | Dec 29, 2025 |
| Listing date (Tentative) | Jun 25, 2026 | Dec 30, 2025 |
| Anchor Lockin End date 1 | Jul 23, 2026 | |
| Anchor Lockin End date 2 | Sep 21, 2026 |
Avience Biomedicals IPO P/E ratio is 11.59, as compared to Sundrex Oil IPO P/E ratio of 10.69.
| Avience Biomedicals IPO | Sundrex Oil IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 87.89% | 100% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 64.59% | 72% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 11.59 | 10.69 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹114.09 Cr. | ₹115.20 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 50.14 | 35.63 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 24.84 | 27.03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.97 | 1.14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹17.94 | ₹8.04 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 49.89 | 35.63 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Avience Biomedicals IPO Retail Individual Investors (RII) are offered 4,81,200 shares while in Sundrex Oil IPO retail investors are offered 4,81,200 shares. Qualified Institutional Buyers (QIB) are offered 2,73,600 shares in Avience Biomedicals IPO and 75,200 shares in Sundrex Oil IPO.
| Avience Biomedicals IPO | Sundrex Oil IPO | |
|---|---|---|
| Anchor Investor Reservation | 4,09,800 shares | 0 shares |
| Market Maker Reservation | 82,200 shares | 1,88,800 shares |
| QIB | 2,73,600 shares | 75,200 shares |
| NII | 2,07,000 shares | 13,96,800 shares |
| RII | 4,81,200 shares | 20,89,600 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 13,71,600 shares | 35,61,600 shares |
Avience Biomedicals IPO subscribed 270.19x in total, whereas Sundrex Oil IPO subscribed 1.53x.
| Avience Biomedicals IPO | Sundrex Oil IPO | |
|---|---|---|
| QIB (times) | 196.77x | 1.00x |
| NII (times) | 597.23x | 1.01x |
| Big NII (times) | 670.18x | 0.97x |
| Small NII (times) | 451.35x | 1.10x |
| RII (times) | 401.36x | 1.90x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 270.19x | 1.53x |
